1428247-78-2
1428247-78-2 structure
- Name: IHVR-17028
- Chemical Name: IHVR-17028
- CAS Number: 1428247-78-2
- Molecular Formula: C23H44N2O5
- Molecular Weight: 428.61
- Catalog: Signaling Pathways Anti-infection Influenza Virus
- Create Date: 2022-01-11 22:31:01
- Modify Date: 2024-01-12 17:40:53
-
IHVR-17028 is a potent and broad-spectrum antiviral agent. IHVR-17028 exhibits antiviral activity against BVDV, TCRV and DENV with EC50 values of 0.4 μM, 0.26 μM, 0.3 μM, respectively. IHVR-17028 is a potent ER α-glucosidase I inhibitor with an IC50 of 0.24 μM. IHVR-17028 can be used for infectious diseases research[1][2].
| Name | IHVR-17028 |
|---|
| Description | IHVR-17028 is a potent and broad-spectrum antiviral agent. IHVR-17028 exhibits antiviral activity against BVDV, TCRV and DENV with EC50 values of 0.4 μM, 0.26 μM, 0.3 μM, respectively. IHVR-17028 is a potent ER α-glucosidase I inhibitor with an IC50 of 0.24 μM. IHVR-17028 can be used for infectious diseases research[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | In virus yield reduction assays, IHVR-17028 inhibits viral activities with EC50 values of 0.4 μM, 0.26 μM, 0.3 μM for bovine viral diarrhea virus (BVDV) (NADL strain), tacaribe virus (TCRV) (11573 strain), DENV (serotype 2, New Guinea C), respectively. And in MTT assays, IHVR-17028 exhibits IC50 values of all >500 μM in MDBK, Huh7.5 or BHK cells[1]. |
| In Vivo | In Pharmacokinetic analysis in rats, IHVR17028 (oral gavage; 75 mg/kg) shows a Cmax value of 0.18 μg/ml; the Tmax value is 1.56 hours; and the F% value is 12% after PO administration, the T1/2 value is 0.88 hour after iv. adminstration[1]. IHVR-17028 (oral gavage; 25-50 mg/kg; treatment 1 day prior to virus challenging) exhibits significant protection in mouse model of lethal MARV infection[1]. Animal Model: BALB/c mice are challenged with 1,000 PFU mouse adapted MARV via IP injection[1] Dosage: 50 mg/kg Administration: Treatment 1 day prior to virus challenging Result: Exhibited protection in mouse when the treatment is initiated 1 day prior to virus challenging. Animal Model: C57B1/6 mice challenged with 1,000 PFU mouse adapted EBOV[1] Dosage: 25 mg/kg Administration: Twice daily at 12 h interval; starting 4 h post infection for 10 days Result: Inhibited EBOV infection in mice. |
| References |
| Molecular Formula | C23H44N2O5 |
|---|---|
| Molecular Weight | 428.61 |